Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
about
The evolution of respiratory Cryptosporidiosis: evidence for transmission by inhalationCryptosporidium and Giardia in Africa: current and future challenges.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theThe impact of asymptomatic helminth co-infection in patients with newly diagnosed tuberculosis in north-west Ethiopia.Treatment of Cryptosporidium: What We Know, Gaps, and the Way ForwardHIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.Advances in the epidemiology, diagnosis and treatment of cryptosporidiosis.Cryptosporidium parvum-specific CD4 Th1 cells from sensitized donors responding to both fractionated and recombinant antigenic proteins.Treatment of parasitic diarrhea in HIV-infected patients.Cryptosporidium parvum at different developmental stages modulates host cell apoptosis in vitro.Batch solar disinfection inactivates oocysts of Cryptosporidium parvum and cysts of Giardia muris in drinking water.Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patientsInfection with Cryptosporidium hominis and reinfection with Cryptosporidium parvum in a transplanted ileum.Treatment of cryptosporidiosis.Lessons Learned from Protective Immune Responses to Optimize Vaccines against Cryptosporidiosis.
P2860
Q27027858-3D1C810D-E53F-4981-BAEE-4A042F9A12C0Q30234730-A07AE43B-A5F3-4FB1-80B5-6EC876EAB784Q34212799-3D93A5C0-EF7F-4037-9011-3CE7F192F7C5Q34404876-F372532A-8F1F-4D64-9D8B-7F81D3CA9132Q34501816-2D30C315-8C88-4E96-BEB2-B2DD61D5DEA9Q35012924-A40E88D0-5097-4E7C-8564-77BE6FC75B9FQ36505502-951794B8-80B2-4857-A4CF-077CB8722D7CQ36576157-E44FCCA8-D315-4434-BE61-844D86D2D32AQ37202848-1EDE32F1-6BEF-46DF-9F77-84434EB020F3Q37523984-4BDA93D8-7049-437A-8E20-8F382C543833Q42015939-4D6423AF-AF38-4B36-B968-CEFC12D0E4CFQ42704322-97FF52DA-2CCC-4158-A87C-307F7C97F445Q44963229-CE6FDF12-2AE0-4DEB-9E95-2A7FEA8DBB4BQ46033411-074A0009-BCB3-4DBE-8DF9-874B4A0753DDQ47733620-5995903A-BE83-4C9C-BE6C-E78AC4C847B5
P2860
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
@en
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
@nl
type
label
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
@en
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
@nl
prefLabel
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
@en
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
@nl
P2093
P1476
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
@en
P2093
P304
P356
10.1016/S0020-7519(03)00093-6
P577
2003-07-01T00:00:00Z